Literature DB >> 4045527

Incidence, course, and severity of delayed nausea and vomiting following the administration of high-dose cisplatin.

M G Kris, R J Gralla, R A Clark, L B Tyson, J P O'Connell, M S Wertheim, D P Kelsen.   

Abstract

Although many trials have evaluated the severity and treatment of nausea and vomiting immediately after cisplatin administration, no studies have focused on vomiting occurring more than 24 hours after chemotherapy--delayed emesis. Two consecutive trials were undertaken to evaluate the incidence, course (trial 1), and severity (trial 2) of delayed nausea and emesis and to develop methods to study these conditions. Eighty-six patients receiving cisplatin (120 mg/m2) for the first time were entered. On the day of cisplatin treatment, all received intravenous (IV) metoclopramide (3 mg/kg X 2 doses) plus dexamethasone (20 mg IV X 1 dose) with either diphenhydramine (50 mg IV) or lorazepam (1.0 to 1.5 mg/m2). Sixty-two percent of patients experienced no vomiting during the 24 hours immediately after administration of cisplatin. Overall, 93% of studied patients experienced some degree of delayed nausea or vomiting from 24 to 120 hours after cisplatin. In trial 1, the incidence of delayed vomiting ranged from 21% to 61% and delayed nausea from 24% to 78% in 58 patients. The highest incidence of both delayed nausea and emesis occurred during the period from 48 to 72 hours after administration of cisplatin. Patients who had no emesis during the initial 24 hours after cisplatin were less likely to experience delayed emesis. The severity of delayed nausea and vomiting was evaluated in 28 patients in trial 2. The amount of delayed nausea and vomiting was assessed daily by patients using a visual analogue scale and by an observer rating. The highest nausea and vomiting scores were seen during the period from 48 to 72 hours after administration of cisplatin, with acceptable correlation between patient scores and observer ratings. Although the nausea and vomiting occurring 24 or more hours after cisplatin administration is not as severe as that seen during the initial 24 hours after administration of cisplatin in patients not receiving antiemetics, it is a common condition that merits both further study and specific treatment.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4045527     DOI: 10.1200/JCO.1985.3.10.1379

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  66 in total

Review 1.  Myths and realities of antiemetic treatment.

Authors:  M Martin
Journal:  Br J Cancer Suppl       Date:  1992-12

Review 2.  Chemotherapy-induced nausea and vomiting: pathophysiology and therapeutic principles.

Authors:  Juan Bayo; Paula J Fonseca; Susana Hernando; S Servitja; A Calvo; S Falagan; Estefanía García; Iria González; María José de Miguel; Quionia Pérez; Ana Milena; Antonio Ruiz; Agustí Barnadas
Journal:  Clin Transl Oncol       Date:  2012-06       Impact factor: 3.405

3.  Chemotherapy-induced nausea and vomiting #285.

Authors:  Nishant Tageja; Hunter Groninger
Journal:  J Palliat Med       Date:  2014-12       Impact factor: 2.947

4.  Corticosteroids, the oldest agent in the prevention of chemotherapy-induced nausea and vomiting: What about the guidelines?

Authors:  Florence Van Ryckeghem
Journal:  J Transl Int Med       Date:  2016-04-14

5.  The serotonin type 3 receptor antagonist BRL 43694 and nausea and vomiting induced by cisplatin.

Authors:  J Carmichael; B M Cantwell; C M Edwards; W G Rapeport; A L Harris
Journal:  BMJ       Date:  1988-07-09

Review 6.  Pharmacological Agents Affecting Emesis : A Review (Part II).

Authors:  F Mitchelson
Journal:  Drugs       Date:  1992-04       Impact factor: 9.546

7.  A dose-finding study of granisetron, a novel antiemetic, in patients receiving high-dose cisplatin. Granisetron Study Group.

Authors:  M Soukop
Journal:  Support Care Cancer       Date:  1994-05       Impact factor: 3.603

Review 8.  Current pharmacotherapy for chemotherapy-induced nausea and vomiting in cancer patients.

Authors:  Michelle C Janelsins; Mohamedtaki A Tejani; Charles Kamen; Anita R Peoples; Karen M Mustian; Gary R Morrow
Journal:  Expert Opin Pharmacother       Date:  2013-04       Impact factor: 3.889

Review 9.  Delayed emesis: a dilemma in antiemetic control.

Authors:  R A Clark; R J Gralla
Journal:  Support Care Cancer       Date:  1993-07       Impact factor: 3.603

Review 10.  Tropisetron. A review of the clinical experience.

Authors:  K M de Bruijn
Journal:  Drugs       Date:  1992       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.